About Remegen
Remegen is a company based in Yantai (China) founded in 2008 by Jianmin Fang and Weidong Wang.. Remegen has raised $100 million across 1 funding round from investors including Orbimed, Lilly Asia Ventures and Lake Bleu Capital. The company has 3,500 employees as of December 31, 2024. Remegen operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Yantai, China
- Employees 3500 as on 31 Dec, 2024
- Founders Jianmin Fang, Weidong Wang
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Remegen Co. Ltd. Class A
-
Annual Revenue
$234.27 M (USD)59.12as on Dec 31, 2024
-
Net Profit
$-201.39 M (USD)2.84as on Dec 31, 2024
-
EBITDA
$-158.92 M (USD)13.22as on Dec 31, 2024
-
Total Equity Funding
$100 M (USD)
in 1 rounds
-
Latest Funding Round
$100 M (USD), Private Equity Round
Mar 16, 2020
-
Investors
Orbimed
& 6 more
-
Employee Count
3500
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Remegen
Remegen is a publicly listed company on the SSE with ticker symbol 688331 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Remegen
Remegen has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Private Equity Round round of $100 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Private Equity Round — $100.0M
-
First Round
First Round
(16 Mar 2020)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Private Equity Round - Remegen | Valuation | Lilly Asia Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Remegen
Remegen has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Lilly Asia Ventures and Lake Bleu Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Remegen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Remegen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Remegen Comparisons
Competitors of Remegen
Remegen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Remegen
Frequently Asked Questions about Remegen
When was Remegen founded?
Remegen was founded in 2008 and raised its 1st funding round 12 years after it was founded.
Where is Remegen located?
Remegen is headquartered in Yantai, China. It is registered at Yantai, Shandong, China.
Who is the current CEO of Remegen?
Jianmin Fang is the current CEO of Remegen. They have also founded this company.
Is Remegen a funded company?
Remegen is a funded company, having raised a total of $100M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $100M, raised on Mar 16, 2020.
How many employees does Remegen have?
As of Dec 31, 2024, the latest employee count at Remegen is 3,500.
What is the annual revenue of Remegen?
Annual revenue of Remegen is $234.27M as on Dec 31, 2024.
What does Remegen do?
Remegen was established in 2008 in Yantai, China, within the biotechnology sector. Antibody-based and fusion protein technologies are utilized to create treatments for cancer, autoimmune conditions, and eye disorders. Antibody-drug conjugates and bifunctional antibodies form key elements of the platform. A notable drug candidate, R18, is advanced as a fusion protein targeting rheumatoid arthritis. Operations emphasize research and development in these therapeutic areas.
Who are the top competitors of Remegen?
Remegen's top competitors include Moderna, argenx and Forge Biologics.
Is Remegen publicly traded?
Yes, Remegen is publicly traded on SSE under the ticker symbol 688331.
Who are Remegen's investors?
Remegen has 7 investors. Key investors include Orbimed, Lilly Asia Ventures, Lake Bleu Capital, Vivo Capital, and Janchor Partners.
What is Remegen's ticker symbol?
The ticker symbol of Remegen is 688331 on SSE.